Every 424B that PARKERVISION INC (PRKR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRKR filings page.
ParkerVision, Inc. supplements its existing prospectus to register the resale of 16,809,295 shares of Common Stock by selling stockholders. The prospectus supplement explains that the registered shares consist of convertible-note conversions, private placements, shares issued for services and payables, and up to 5,000,000 and 200,000 shares issuable upon exercise of warrants held by Aspire Capital and Tailwinds, respectively.
The company states it will not receive proceeds from the resale by selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to an aggregate of $3,900,000, which it expects to use for general working capital and corporate purposes. The supplement incorporates a Form 8-K dated March 13, 2026 describing exchange agreements that resulted in issuance of 3,277,099 shares to cancel convertible notes with aggregate principal of $675,000.
ParkerVision, Inc. files a prospectus supplement registering 18,014,164 shares of Common Stock for resale by selling stockholders under its existing prospectus.
The supplement states the registered shares consist of convertible-note conversions, consulting-share issuances and a warrant, and that the company will not receive proceeds from resales by the selling stockholders. The supplement also attaches an 8-K dated March 13, 2026 reporting that the company issued 3,277,099 shares pursuant to exchanges that cancelled convertible notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest, issued at an exchange price of $0.21 per share.
ParkerVision, Inc. files a prospectus supplement to register 17,189,660 shares of Common Stock for resale by selling stockholders under prior registration statements. The supplement incorporates the Company’s Form 8-K dated March 13, 2026 concerning exchange transactions.
Separately, the Company issued 3,277,099 shares of Common Stock on March 13, 2026, in exchange under Section 3(a)(9) for cancellation of convertible notes with an aggregate principal of $675,000 plus approximately $13,200 of accrued interest at an exchange price of $0.21 per share.
ParkerVision, Inc. registered 12,800,000 shares of Common Stock by prospectus supplement dated March 13, 2026.
The supplement states the 12,800,000 shares consist of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 to fund patent enforcement and working capital.
Separately, the company entered into exchange agreements dated March 13, 2026 to cancel convertible notes: the company issued 3,277,099 shares at an exchange price of $0.21 per share in exchange for cancellation of notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest.
ParkerVision, Inc. filed a prospectus supplement tied to an existing resale registration covering up to 9,387,500 shares of common stock. These shares include stock already issued under prior securities purchase agreements, shares issuable upon conversion of certain convertible notes at a fixed price of $0.16 per share, and shares issuable upon exercise of options granted as payment for services. The company will not receive proceeds from resales by the selling shareholders, but could receive up to $42,620 in gross proceeds if the service options are exercised for cash.
Separately, the compensation committee granted performance-based stock options for up to 8,000,000 shares to the CEO and 500,000 shares to the CFO, plus a time-based option for 500,000 shares to the CFO, all with a $0.24 exercise price. The performance options vest based on cumulative net cash from patent enforcement actions and can accelerate if the company’s market capitalization reaches $1 billion for twenty consecutive trading days or upon a change in control. The committee also approved a 2.5% cost-of-living increase to the CEO’s and CFO’s base salaries.
ParkerVision, Inc. filed a prospectus supplement that updates its existing resale registration covering up to 16,638,353 shares of common stock issuable upon conversion of, and as interest paid in stock on, convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share.
The supplement incorporates a recent report describing new equity incentives for executives. The compensation committee granted performance-based stock options to the CEO for up to 8,000,000 shares and to the CFO for up to 500,000 shares, plus a time-based option for the CFO for up to 500,000 shares, all with a $0.24 exercise price. Vesting for the performance awards is tied to cumulative net cash from patent enforcement actions, with accelerated vesting if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CEO and CFO also received a 2.5% cost-of-living salary increase effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement covering the resale by a selling stockholder of up to 1,578,946 shares of common stock, including 1,052,631 existing shares and 526,315 shares issuable upon exercise of warrants. The company will not receive proceeds from resales, but could receive up to $526,315 in gross proceeds if the warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses.
The attached report also describes new equity awards for executives under the 2019 Long-Term Incentive Plan. The CEO received a performance-based option for up to 8,000,000 shares and the CFO received a performance-based option for up to 500,000 shares, both with a $0.24 exercise price, a five-year performance period with quarterly measurement dates, and ten-year terms, vesting based on cumulative net cash from patent enforcement actions. Vesting accelerates if market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares at $0.24, vesting over two years, and both executives received a 2.5% cost-of-living salary increase effective April 15, 2026.
ParkerVision, Inc. has a prospectus supplement covering the resale by existing stockholders of up to 13,342,953 shares of common stock, including shares previously issued in securities purchase agreements, shares underlying warrants, and shares issued as payment for services. The company will not receive any proceeds from stockholder resales, but could receive up to $2,833,756 in gross proceeds if the associated warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses.
The filing also describes new equity incentives for executives. The CEO received a performance-based stock option for up to 8,000,000 shares and the CFO received a performance-based option for up to 500,000 shares, both with a $0.24 exercise price and a five-year performance period tied to cumulative net cash from patent enforcement actions. These options fully vest early if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares at $0.24 per share, and both executives were granted a 2.5% cost-of-living base salary increase.
ParkerVision, Inc. filed a prospectus supplement covering the resale by existing holders of up to 5,871,584 shares of common stock; the company will not receive any proceeds from these sales. The supplement incorporates a new current report detailing significant equity incentives for senior management.
The compensation committee granted the CEO a performance-based stock option for up to 8,000,000 shares and the CFO a performance-based option for up to 500,000 shares, each with a five-year performance period, ten-year term, and an exercise price of $0.24 per share. Vesting depends on cumulative net cash received from patent enforcement actions and can accelerate if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares vesting over two years, and both executives will receive a 2.5% cost-of-living salary increase effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement tied to an existing resale registration covering up to 16,809,295 shares of common stock. These shares include stock issued in prior financings and services, as well as shares issuable upon conversion of earlier convertible notes and upon exercise of warrants held by Aspire Capital Fund LLC and Tailwinds Research Group LLC. The company will not receive proceeds from stockholder resales, but could receive up to $3,900,000 in gross proceeds if the Aspire and Tailwinds warrants are exercised for cash.
The attached current report describes new equity incentives for executives under the 2019 Long-Term Incentive Plan. The Compensation Committee granted a performance-based stock option for up to 8,000,000 shares to the CEO and up to 500,000 shares to the CFO, both with a five-year performance period and a ten-year term, at an exercise price of $0.24 per share. Vesting depends mainly on cumulative net cash from patent enforcement actions, with automatic acceleration if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares and a 2.5% cost-of-living salary increase, matching a similar increase for the CEO.
ParkerVision, Inc. filed a prospectus supplement covering the resale of up to 18,014,164 shares of common stock by existing holders. These shares come from prior convertible notes, consulting share issuances, and a warrant granted for services. The company will not receive any proceeds from stockholder resales, but may receive up to $180,000 if a service-related warrant is exercised for cash, which would be used for working capital and general corporate purposes.
The attached current report also describes new equity compensation for executives. The CEO received a performance-based option for up to 8,000,000 shares and the CFO received performance-based options for up to 500,000 shares, all at an exercise price of $0.24 per share, with vesting tied to net cash from patent enforcement and certain market capitalization or change-of-control triggers. The CFO also received a separate time-based option for up to 500,000 shares and both executives were granted a 2.5% cost-of-living salary increase.
ParkerVision, Inc. files a prospectus supplement covering the resale by existing holders of up to 17,189,660 shares of common stock previously registered under earlier shelf and resale statements. The company will not receive proceeds from these stockholder resales, but may receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from stock sales or warrant exercises under its agreement with Aspire Capital, which it expects to use for patent enforcement and general corporate purposes.
The attached report also discloses new performance-based stock option grants under the 2019 plan: up to 8,000,000 shares for the CEO and 500,000 shares for the CFO, vesting over a five-year performance period tied to net cash from patent enforcement, with accelerated vesting if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also receives a time-based option for up to 500,000 shares and both executives receive a 2.5% cost-of-living base salary increase.
ParkerVision, Inc. updates its resale prospectus covering up to 12,800,000 shares of common stock, which may be sold from time to time by existing selling stockholders. The company will not receive proceeds from these resales, but could receive up to $800,000 in gross proceeds if an associated warrant is exercised for cash, which it expects to use for patent enforcement actions and general working capital.
The company also approved new nonqualified stock option grants under its 2019 Long-Term Incentive Plan. The CEO received a performance-based option for up to 8,000,000 shares and the CFO a performance-based option for up to 500,000 shares, both with a five-year performance period and a ten-year term, at an exercise price of $0.24 per share. Vesting is tied to cumulative net cash from patent enforcement actions and may accelerate if market capitalization reaches $1 billion for twenty consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares vesting over two years, and both executives will receive a 2.5% cost-of-living base salary increase effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement that continues to permit the resale by existing shareholders of up to 9,387,500 shares of common stock. These shares include 2,843,750 shares already issued under prior securities purchase agreements, 6,343,750 shares issuable upon conversion or interest payments on convertible notes at a fixed conversion price of $0.16 per share, and 200,000 shares issuable upon exercise of options granted for services. The company will not receive proceeds from shareholder resales but could receive up to $42,620 if the options are exercised for cash.
The supplement also incorporates a new Form 8-K, which reports that on November 24, 2025 ParkerVision completed a separate registered offering and sale of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. No underwriters, placement agents, brokers, or finders were engaged, and no commissions or fees were paid.
ParkerVision, Inc. has a prospectus supplement allowing the selling shareholders to resell up to 16,638,353 shares of common stock issuable upon conversion and interest payments on certain 2022 convertible notes with a fixed conversion price of $0.13 per share. The supplement incorporates a new Form 8-K that reports a separate capital raise completed on November 24, 2025.
In that transaction, the company sold 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its effective shelf registration statement on Form S-3. No underwriters, placement agents, brokers, or finders were involved, so no commissions or fees were paid. A subscription agreement and a press release describing the closing are filed as exhibits.
ParkerVision, Inc. is registering for resale up to 1,578,946 shares of common stock under a prospectus supplement that also incorporates a recent equity financing update. The registered amount includes 1,052,631 outstanding shares of common stock and 526,315 shares issuable upon exercise of warrants issued under a December 14, 2021 securities purchase agreement. The company will not receive any proceeds from resale of these shares, but could receive up to $526,315 in gross proceeds if the warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses. Separately, ParkerVision completed a primary offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off its shelf registration statement without underwriters or fees.
ParkerVision, Inc. has filed a prospectus supplement covering the resale of up to 13,342,953 shares of common stock by selling stockholders. These shares include 7,962,722 shares issued under prior securities purchase agreements, 3,230,942 shares plus 1,619,289 warrant shares from March 29, 2021 agreements, and 530,000 shares issued as payment for services. The company will not receive proceeds from resales, but could receive up to $2,833,756 in gross proceeds if the related warrants are exercised for cash, which it expects to use for working capital and litigation expenses.
The supplement also attaches a Form 8-K describing a completed offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off the company’s shelf registration statement. No underwriters, placement agents, brokers, or finders were used, and no commissions or fees were paid in connection with this primary offering.
ParkerVision, Inc. has filed a prospectus supplement tied to an existing resale registration that permits selling stockholders to resell up to 5,871,584 shares of its common stock issued under prior securities purchase agreements. The company will not receive any proceeds from these resale transactions. The supplement updates the prospectus by incorporating a new Form 8-K.
The attached Form 8-K reports that on November 24, 2025, ParkerVision completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its shelf registration statement on Form S-3. The company conducted this primary offering without underwriters, placement agents, brokers, or finders and paid no commissions or fees.
ParkerVision, Inc. updated its April 2020 resale prospectus to cover up to 16,809,295 shares of common stock that may be sold from time to time by existing stockholders. These shares include stock already issued, shares issuable from convertible notes, and up to 5,200,000 shares underlying warrants held by Aspire Capital and Tailwinds. The company will not receive proceeds from stockholder resales, but could receive up to $3,900,000 if the Aspire and Tailwinds warrants are exercised for cash.
Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. The company did not use underwriters or pay commissions in this transaction, and disclosed the closing and related agreements through its Form 8-K and attached exhibits.
ParkerVision, Inc. has an effective prospectus supplement that permits the resale by existing stockholders of up to 18,014,164 shares of common stock. These consist of up to 5,457,583 shares issuable under Tranche 1 convertible notes at a fixed conversion price of $0.10 per share, up to 10,131,581 shares issuable under Tranche 2 convertible notes at a fixed conversion price of $0.08 per share, 625,000 shares issued for services under the Fisher Consulting Agreement, and up to 1,800,000 shares issuable upon exercise of the Park Consulting Warrant with a $0.10 exercise price.
The company will not receive proceeds from resale of these shares by selling stockholders, but could receive up to $180,000 in gross proceeds if the Park Consulting Warrant is exercised for cash. Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its Form S-3 shelf registration statement, with no commissions or fees paid.
ParkerVision, Inc. has filed a prospectus supplement covering the resale by existing stockholders of up to 17,189,660 shares of common stock. These shares include stock and warrants from a 2016 private placement, shares issued and issuable under a 2018 PIPE agreement with Aspire Capital, and shares issuable upon conversion of 2018 convertible notes. The company will not receive proceeds from stockholder resales, but could receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from sales of common stock or warrant exercises under the Aspire Capital agreement.
Separately, ParkerVision completed a registered direct offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its Form S-3 shelf registration. No underwriters, placement agents, brokers, or finders were involved and no commissions or fees were paid.
ParkerVision, Inc. has filed a prospectus supplement that continues to permit the resale by selling stockholders of up to 12,800,000 shares of common stock previously registered under its shelf program. These shares consist of up to 7,800,000 shares issuable upon conversion of, or payment of interest on, convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.
The company will not receive proceeds from resale of these shares, but could receive up to $800,000 in gross proceeds if the warrant is exercised for cash, which it expects to use for patent enforcement, working capital, and general corporate purposes. The attached Form 8-K discloses that ParkerVision also completed a separate registered offering of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, with no commissions or fees paid.
ParkerVision, Inc. completed a primary offering of 16,481,579 shares of common stock to accredited investors at $0.21 per share, raising gross proceeds of $3,461,132. The shares were sold directly under subscription agreements without underwriters or placement agents, and the deal closed on November 24, 2025.
The company plans to use the cash for working capital, general corporate purposes, and litigation fees and expenses, which align with its IP-enforcement focused business model. On a pro forma basis as of September 30, 2025, cash would increase from $901,000 to $5,470,000, and total shareholders’ deficit would narrow from $(49.8) million to $(45.2) million, though the balance sheet remains highly leveraged.
The offering price creates meaningful dilution. Pro forma as adjusted net tangible book value moves from $(0.39) to $(0.32) per share, implying an immediate dilution of $0.53 per share to new investors buying at $0.21. The company continues to highlight substantial risks, including a limited OTCQB trading market, a need for additional capital, and going concern language in its audited financial statements.
ParkerVision, Inc. completed a registered direct offering of 4,761,905 shares of common stock to board member Lewis H. Titterton, Jr. for $1,000,000, priced at $0.21 per share, equal to the last reported OTCQB sale price on November 14, 2025. The company received the full amount with no underwriting or placement fees.
Shares outstanding increase from 121,549,398 to 126,311,303, and the transaction causes immediate dilution, with pro forma net tangible book value rising from approximately $(0.42) to $(0.40) per share. Management plans to use the net proceeds for working capital and other general corporate purposes, including litigation fees and expenses, as ParkerVision continues to focus on enforcing its RF patent portfolio.
ParkerVision, Inc. has filed a prospectus supplement that allows selling shareholders to resell up to 9,387,500 shares of common stock, primarily from previously issued shares and shares underlying convertible notes and options. The company will not receive proceeds from these resales, and would receive only up to $42,620 if certain options are exercised for cash.
Attached to the supplement is ParkerVision’s latest quarterly report, showing a net loss of about $7.4 million for the nine months ended September 30, 2025 and no revenue. Cash and cash equivalents were roughly $0.9 million against current liabilities of about $2.9 million, including $1.6 million of convertible debt due within a year, and large long-term contingent payment obligations. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern without new licensing wins, successful litigation outcomes or additional financing.